GNLX
NASDAQGenelux Corporation
Price$2.88-0.10 (-3.35%)
01:45 PM07:45 PM
News · 26 weeks34-75%
2025-12-142026-06-07
Mix1990d
- Insider10(53%)
- SEC Filings7(37%)
- Offering1(5%)
- Other1(5%)
Latest news
25 items- INSIDERHead of Regulatory Smalling Ralph sold $563 worth of shares (192 units at $2.93), decreasing direct ownership by 0.28% to 67,611 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERDirector Thomas John sold $29,801 worth of shares (10,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 472,784 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERChief Technical Officer Cappello Joseph sold $1,799 worth of shares (605 units at $2.97), decreasing direct ownership by 0.39% to 154,549 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERChief Scientific Officer Yu Yong sold $1,798 worth of shares (605 units at $2.97), decreasing direct ownership by 0.40% to 149,706 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERHead of Regulatory Smalling Ralph sold $804 worth of shares (270 units at $2.98), decreasing direct ownership by 0.40% to 67,803 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERPresident and CEO Zindrick Thomas sold $8,226 worth of shares (2,798 units at $2.94), decreasing direct ownership by 0.52% to 532,051 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- PRGenelux Corporation Reports First Quarter Financial Results and Provides Business Updates-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026; expected to fund operations into 1Q27 -- WESTLAKE VILLAGE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates. "As we build on our momentum entering 2026, we remain focused on disciplined exec
- SECSEC Form 10-Q filed by Genelux Corporation10-Q - GENELUX Corp (0001231457) (Filer)
- SECSEC Form DEFA14A filed by Genelux CorporationDEFA14A - GENELUX Corp (0001231457) (Filer)
- SECSEC Form DEF 14A filed by Genelux CorporationDEF 14A - GENELUX Corp (0001231457) (Filer)
- INSIDERSEC Form 4 filed by Zindrick Thomas4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERSEC Form 4 filed by Smalling Ralph4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERSEC Form 4 filed by Yu Yong4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERSEC Form 4 filed by Cappello Joseph4 - GENELUX Corp (0001231457) (Issuer)
- SECSEC Form 424B5 filed by Genelux Corporation424B5 - GENELUX Corp (0001231457) (Filer)
- SECSEC Form S-8 filed by Genelux CorporationS-8 - GENELUX Corp (0001231457) (Filer)
- SECGenelux Corporation filed SEC Form 8-K: Financial Statements and Exhibits8-K - GENELUX Corp (0001231457) (Filer)
- PRGenelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 -- -- Appointed Jason Litten, M.D., as Chief Medical Officer to lead clinical development strategy -- -- $33.1 million in pro forma cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025, including $18.5 million in net proceeds from underwritten offering of common stock in January 2026; expected to su
- SECSEC Form 10-K filed by Genelux Corporation10-K - GENELUX Corp (0001231457) (Filer)
- INSIDERDirector Thomas John sold $28,957 worth of shares (10,000 units at $2.90), decreasing direct ownership by 2% to 482,784 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- PRGenelux Corporation to Participate in Upcoming ConferencesWESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.TD Cowen 46th Annual Health Care Conference: Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, Chief Financial Officer, will participate in a presentation on Monda
- SECGenelux Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - GENELUX Corp (0001231457) (Filer)
- PRGenelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan PartnersWESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT. A live webcast of the fireside chat can be found here and on the investor relations section of the Company's website at https://investors.genelux.com/. Following the live webcast, an archived replay wi
- SECGenelux Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - GENELUX Corp (0001231457) (Filer)
- SECSEC Form 424B5 filed by Genelux Corporation424B5 - GENELUX Corp (0001231457) (Filer)
GNLX FAQ
6 questionsWhere does GNLX stock trade?
Genelux Corporation (GNLX) is listed on NASDAQ.What sector and industry is GNLX in?
Genelux Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Genelux Corporation go public?
Genelux Corporation (GNLX) completed its IPO in 2023.What are analysts saying about GNLX?
Genelux Corporation has had 6 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $1600.00 price target on 2025-10-21. Recent price targets range from $800.00 to $4000.00.What companies are similar to GNLX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GNLX side-by-side with any of them on Quantisnow.How can I track GNLX on Quantisnow?
Quantisnow aggregates Genelux Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNLX to receive live email and push alerts on every new disclosure.